AVANIR PHARMACEUTICALS

9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 93121-3016, 6195580364
PHARMACEUTICAL PREPARATIONS

1998 SEC Filings

AVANIR PHARMACEUTICALS, NT 10-K, 1998-12-30
AVANIR PHARMACEUTICALS, 8-K, 1998-12-23
AVANIR PHARMACEUTICALS, PRE 14A, 1998-12-16
AVANIR PHARMACEUTICALS, 8-K, 1998-12-07
LIDAK PHARMACEUTICALS, 8-K, 1998-10-30
LIDAK PHARMACEUTICALS, DEFA14A, 1998-10-02
LIDAK PHARMACEUTICALS, DEFA14A, 1998-09-30
LIDAK PHARMACEUTICALS, DEFS14A, 1998-09-30
LIDAK PHARMACEUTICALS, PRER14A, 1998-09-21
LIDAK PHARMACEUTICALS, SC 13D/A, 1998-09-18
LIDAK PHARMACEUTICALS, PRES14A, 1998-09-17
LIDAK PHARMACEUTICALS, 4, 1998-09-10
LIDAK PHARMACEUTICALS, SC 13D/A, 1998-09-03
LIDAK PHARMACEUTICALS, 10-Q, 1998-08-14
LIDAK PHARMACEUTICALS, 8-K, 1998-07-27
LIDAK PHARMACEUTICALS, 4, 1998-07-10
LIDAK PHARMACEUTICALS, DEFA14A, 1998-06-12
LIDAK PHARMACEUTICALS, 4, 1998-06-10
LIDAK PHARMACEUTICALS, DEFR14A, 1998-05-06
LIDAK PHARMACEUTICALS, 8-K, 1998-05-06
LIDAK PHARMACEUTICALS, DEF 14A, 1998-05-01
LIDAK PHARMACEUTICALS, 8-K, 1998-04-27
LIDAK PHARMACEUTICALS, PRE 14A, 1998-04-27
LIDAK PHARMACEUTICALS, 10-Q, 1998-04-24
LIDAK PHARMACEUTICALS, SC 13D/A, 1998-04-02
LIDAK PHARMACEUTICALS, SC 13D, 1998-03-30
LIDAK PHARMACEUTICALS, 8-K, 1998-03-27
LIDAK PHARMACEUTICALS, DEFA14A, 1998-03-27
LIDAK PHARMACEUTICALS, 8-K, 1998-03-18
LIDAK PHARMACEUTICALS, PREC14A, 1998-03-17
LIDAK PHARMACEUTICALS, DEFA14A, 1998-03-17
LIDAK PHARMACEUTICALS, SC 13D/A, 1998-03-16
LIDAK PHARMACEUTICALS, DEF 14A, 1998-03-13
LIDAK PHARMACEUTICALS, 8-K, 1998-03-12
LIDAK PHARMACEUTICALS, 8-K, 1998-03-03
LIDAK PHARMACEUTICALS, 10-Q/A, 1998-02-19
LIDAK PHARMACEUTICALS, 10-Q, 1998-02-18
LIDAK PHARMACEUTICALS, NT 10-Q, 1998-02-18
LIDAK PHARMACEUTICALS, 4, 1998-02-10
LIDAK PHARMACEUTICALS, POS AM, 1998-01-29
LIDAK PHARMACEUTICALS, 10-K405/A, 1998-01-28
LIDAK PHARMACEUTICALS, SC 13D, 1998-01-22
LIDAK PHARMACEUTICALS, 8-K, 1998-01-21
LIDAK PHARMACEUTICALS, 10-K/A, 1998-01-09
LIDAK PHARMACEUTICALS, 10-K405, 1998-01-02
LIDAK PHARMACEUTICALS, 8-K, 1998-01-02


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission